There are several types of vaccines that can be used to fight diseases. Inactivated vaccines are composed of dead, or inactivated, viruses and bacteria, and therefore differ from live but attenuated vaccines. The type of vaccine used can differ depending on the infection in question, how the immune system responds to the pathogen the vaccine will treat, and various practical considerations related to the delivery of the vaccine.

How do inactivated vaccines work?

Many vaccines that are regularly used, such as the MMR vaccines and chickenpox vaccines, are live attenuated vaccines. These vaccines have a weakened version of the live virus, to stop it from causing the disease but to still encourage the production of T cells. Inactivated vaccines are another form of vaccine, where the virus is inactivated during the process of making the vaccine.

Inactivated vaccines are not strongly influenced by antibodies in the host body, compared to live vaccines. This means that they can be administered when antibodies are present in the blood, such as during infancy or after being given medication containing antibodies.

Inactivated vaccines cannot replicate and always require repeated doses for immunity to be achieved. The first dose is the one that prepares the immune system to respond, but a protective immune response does not develop until the second or later doses.

Because the virus is dead during the making of the vaccine, they interact with the immune system differently than live, attenuated vaccines. The immune response to live vaccines is similar to encountering the virus itself, whereas inactivated vaccines show little or no cellular immunity. This also means that inactivated vaccines can be used to boost to supplement previous vaccinations.

How are inactivated vaccines made?

To make an inactivated vaccine, the virus has to be grown in culture media. This can often be an initial limiting step in vaccine production, as producers need to understand what conditions encourage viral growth.

Inactivation of the virus is done with heat. Occasionally, inactivation is done with chemicals such as formalin. When the vaccine under production it is fractional, meaning it is protein or polysaccharide-based, the vaccine undergoes further purification so that only the subunits of interest remain.

What pathogens can be treated with inactivated vaccines?

Most inactivated vaccines are available as whole-cell inactivated vaccines. These can target viruses such as polio, hepatitis A, and rabies. There are also fractional vaccines for hepatitis B, anthrax, and toxoids such as tetanus.

Several inactivated vaccines have been discontinued. Inactivated vaccines for influenza and bacterial diseases like typhoid, cholera, and plague. There are also subunit vaccines for Lyme disease that have been discontinued.

The use of inactivated vaccines, as opposed to live attenuated vaccines, is a contentious issue. For example, inactivated vaccines for influenza are currently available as subunit, rather than whole viral vaccines, in the US. Live, attenuated vaccines can, in rare cases, cause infection of the pathogen and use of it for influenza has caused hospitalization in some children and elderly. This has led to the recommendation of using inactivated vaccines, instead.

Conclusion

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at autoimmunedis@eclinicalsci.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com